Dshm.Ns
DSHM.NS is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of pharmaceutical products.
Business. DSHM.NS is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
DSHM.NS is a pharmaceutical company that generates revenue primarily through the development, manufacturing, and sale of pharmaceutical products.
DSHM.NS has a debt-to-equity ratio of 0.41, indicating a relatively conservative capital structure with a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 1.14, suggesting it has just enough current assets to cover its current liabilities. However, the company's net cash position is negative after subtracting total debt, which could signal potential liquidity constraints in the short term.
Profitability metrics for DSHM.NS are weak, with a return on equity (ROE) of 0.06% and a return on assets (ROA) of 0.03%. These figures are significantly below the typical performance benchmarks for the pharmaceutical industry, indicating that the company is not effectively utilizing its equity or assets to generate returns. The operating income of INR 1.68 billion and net income of INR 32.4 million further underscore the company's limited profitability.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification could expose the company to higher risks if market conditions in its primary operating region deteriorate.
DSHM.NS has shown a modest growth trajectory, with a revenue of INR 27.12 billion in the latest reporting period. However, the outlook for the next fiscal year does not indicate a significant increase in revenue, suggesting a stable but not growing business. The company's capital expenditures were negative at INR 2.17 billion, indicating a reduction in investment in long-term assets, which may affect its future growth potential.
The risk assessment for DSHM.NS highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations. However, the dilution risk is low, as there is no indication of significant share issuance or dilution potential in the near term.
Recent filings and transcripts do not provide specific details on new product launches, partnerships, or strategic initiatives. The company's financial performance and risk profile suggest a need for strategic improvements to enhance profitability and liquidity. The absence of recent significant events or disclosures implies a relatively stable but underperforming business environment.
- DSHM.NS has a conservative capital structure with a debt-to-equity ratio of 0.41, but its liquidity position is assessed as medium.
- The company's profitability is weak, with a return on equity of 0.06% and a return on assets of 0.03%, significantly below industry benchmarks.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed, increasing exposure to regional market risks.
- The company's growth trajectory is modest, with a revenue of INR 27.12 billion and no significant increase expected in the next fiscal year.
- DSHM.NS faces a medium liquidity risk due to a negative net cash position after subtracting total debt, but the dilution risk is low.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- DSHM.NS Market data — financials · 2026-05-27